Chronic obstructive pulmonary disease (COPD) remains a substantial contributor to morbidity and mortality in the United States with an estimated 3.8% age-adjusted prevalence and 141,733 COPD deaths ...

Obstructive lung diseases like COPD cause trouble when you're exhaling air. Restrictive lung diseases like pulmonary fibrosis make it harder to inhale air, reducing total lung capacity. There are two ...

Extrafine single-inhaler triple therapy with BDP/FF/GB is effective for improving health-related quality of life and lung function in COPD.

The experimental drug reduced flare-ups for patients with chronic obstructive pulmonary disease, Astra said Friday.

WILMINGTON, Del.--(BUSINESS WIRE)--The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of ...

By Pushkala Aripaka, Nithyashree R B and Maggie Fick March 27 (Reuters) - AstraZeneca's experimental drug tozorakimab reduced ...

TARRYTOWN, N.Y. and PARIS, May 30, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a Phase 3 trial, AERIFY-1, evaluating the investigational use ...

Southern California's Salton Sea was once a resort playground, with sunny beaches, celebrities and people waterskiing on the vast inland lake in the 1950s and '60s. A new study from the University of ...

Chronic obstructive pulmonary disease (COPD) is the world’s third leading cause of death. Although often overlooked, it is still widespread, currently affecting around 391 million individuals ...

When one thinks of who is most likely to develop chronic obstructive pulmonary disease (COPD), a group of progressive, chronic lung diseases caused by inflammation and damage to the lungs, one ...